Literature DB >> 17291380

Secular trends in the epidemiology of shingles in Alberta.

M L Russell1, D P Schopflocher, L Svenson, S N Virani.   

Abstract

Varicella vaccine was licensed in Canada in 1998, and a publicly funded vaccination programme introduced in the province of Alberta in 2001. In theory the vaccination programme might increase the burden of disease from shingles, making it important to develop baseline data against which future comparisons can be made. The study's aim was to describe the epidemiology of non-fatal cases of shingles for which publicly funded health services were utilized for the period 1986-2002. Shingles cases were identified from the records of Alberta's universal, publicly funded health-care insurance system for 1986-2002. The earliest dated health service utilizations for ICD-9-CM codes of 053 or ICD-10-CA codes of B02 were classified as incident. Diagnostic codes at least 180 days after the first were classified as recurrent episodes. Denominators for rates were estimated using mid-year population estimates from the Alberta Health Care Insurance Plan Registry. Annual age- and sex-specific rates were estimated. We explored the pattern of rates for sex, age and year effects and their interactions. Shingles rates increased between 1986 and 2002. There was a sex effect and evidence of an age-sex interaction. Females had higher rates than males at every age; however, the difference between females and males was greatest for the 50-54 years age group and declined for older age groups. The increased rate of shingles in Alberta began before varicella vaccine was licensed or publicly funded in Alberta, and thus cannot be attributed to vaccination.

Mesh:

Substances:

Year:  2007        PMID: 17291380      PMCID: PMC2870667          DOI: 10.1017/S0950268807007893

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  13 in total

1.  Geographic and racial aspects of herpes zoster.

Authors:  Elna M Nagasako; Robert W Johnson; David R J Griffin; David J Elpern; Robert H Dworkin
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

2.  Epidemiology of Varicella-Zoster Virus in England and Wales.

Authors:  M Brisson; W J Edmunds
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

3.  The incidence of shingles and its implications for vaccination policy.

Authors:  Rachel S Chapman; Kenneth W Cross; Douglas M Fleming
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

4.  Gender difference in the incidence of shingles.

Authors:  D M Fleming; K W Cross; W A Cobb; R S Chapman
Journal:  Epidemiol Infect       Date:  2004-01       Impact factor: 2.451

5.  Incidence of herpes zoster, 1997-2002.

Authors:  J P Mullooly; K Riedlinger; C Chun; S Weinmann; H Houston
Journal:  Epidemiol Infect       Date:  2005-04       Impact factor: 2.451

6.  Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV.

Authors:  M Brisson; W J Edmunds; N J Gay
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

7.  Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.

Authors:  M Brisson; W J Edmunds; B Law; N J Gay; R Walld; M Brownell; L L Roos; L Roos; G De Serres
Journal:  Epidemiol Infect       Date:  2001-10       Impact factor: 2.451

8.  The incidence of herpes zoster.

Authors:  J G Donahue; P W Choo; J E Manson; R Platt
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

9.  Doctors, patients and influenza-like illness: clinicians or patients at risk?

Authors:  N Yiannakoulias; M L Russell; L W Svenson; D P Schopflocher
Journal:  Public Health       Date:  2004-10       Impact factor: 2.427

10.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

View more
  31 in total

Review 1.  Annual adult health checkup: update on the Preventive Care Checklist Form(©).

Authors:  Anthony Duerksen; Vinita Dubey; Karl Iglar
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

2.  Zoster vaccination: A new opportunity for adult immunization.

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Re: secular trends in the epidemiology of shingles in Alberta.

Authors:  Carlo Gagliotti
Journal:  Epidemiol Infect       Date:  2008-04       Impact factor: 2.451

4.  Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study.

Authors:  Kosuke Kawai; Barbara P Yawn; Peter Wollan; Rafael Harpaz
Journal:  Clin Infect Dis       Date:  2016-05-08       Impact factor: 9.079

5.  Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?

Authors:  Barbara P Yawn; Peter Wollan; Jennifer St Sauver
Journal:  Am J Epidemiol       Date:  2011-09-13       Impact factor: 4.897

6.  Herpes zoster recurrences more frequent than previously reported.

Authors:  Barbara P Yawn; Peter C Wollan; Marge J Kurland; Jennifer L St Sauver; Patricia Saddier
Journal:  Mayo Clin Proc       Date:  2011-01-10       Impact factor: 7.616

7.  Long-term persistence of zoster vaccine efficacy.

Authors:  Vicki A Morrison; Gary R Johnson; Kenneth E Schmader; Myron J Levin; Jane H Zhang; David J Looney; Robert Betts; Larry Gelb; John C Guatelli; Ruth Harbecke; Connie Pachucki; Susan Keay; Barbara Menzies; Marie R Griffin; Carol A Kauffman; Adriana Marques; John Toney; Kathy Boardman; Shu-Chih Su; Xiaoming Li; Ivan S F Chan; Janie Parrino; Paula Annunziato; Michael N Oxman
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

8.  Literature Review on One-Dose and Two-Dose Varicella Vaccination: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Alexia Campbell; Shainoor Ismail; Ben Tan
Journal:  Can Commun Dis Rep       Date:  2010-10-18

9.  Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

Authors:  María D Esteban-Vasallo; M Felicitas Domínguez-Berjón; Ruth Gil-Prieto; Jenaro Astray-Mochales; Angel Gil de Miguel
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

10.  Examination of links between herpes zoster incidence and childhood varicella vaccination.

Authors:  Craig M Hales; Rafael Harpaz; M Riduan Joesoef; Stephanie R Bialek
Journal:  Ann Intern Med       Date:  2013-12-03       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.